meropenem and Uremia

meropenem has been researched along with Uremia* in 3 studies

Reviews

1 review(s) available for meropenem and Uremia

ArticleYear
Infective endocarditis developing as uremia.
    Internal medicine (Tokyo, Japan), 2005, Volume: 44, Issue:6

    A 49-year-old man presented with fever and uremic symptoms such as general malaise, leg edema and decreased urine output. He was diagnosed as having infective endocarditis (IE) accompanied by renal failure. Although he had been receiving hemodialysis for a long time, renal function dramatically improved after heart valve replacement. This case suggests that uremia can develop as an initial manifestation of IE and removal of an infected heart valve can improve renal function despite persistent renal failure. From the perspective of recovery of renal function, early surgery should be considered in patients with renal failure following IE.

    Topics: Anuria; Aortic Valve; Diagnosis, Differential; Echocardiography, Doppler; Endocarditis, Bacterial; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Male; Meropenem; Middle Aged; Thienamycins; Uremia

2005

Other Studies

2 other study(ies) available for meropenem and Uremia

ArticleYear
Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
    Antimicrobial agents and chemotherapy, 1992, Volume: 36, Issue:12

    The pharmacokinetics of meropenem (ICI 194,660) and its open-ring metabolite (ICI 213,689) were studied in 6 healthy volunteers and 16 patients with moderate to severe renal impairment after a single intravenous dose of 500 mg given as a 30-min infusion. Concentrations of unchanged meropenem in plasma and urine were measured by both microbiological and high-pressure liquid chromatographic (HPLC) assays. A good correlation was found between the two techniques. Pharmacokinetic parameters of unchanged meropenem were determined by using the HPLC data. The terminal half-life of unchanged meropenem increased in relation to the degree of renal impairment, being 1.2 h in subjects with normal renal function and 10 h in patients with end-stage renal failure. Total body clearance and renal clearance of unchanged meropenem are linearly related to creatinine clearance. The concentrations of the metabolite in plasma, which are very low in healthy subjects, significantly increased in uremic patients. The apparent half-life of ICI 213,689 increased in uremic patients and was about 35 h in patients with severe renal insufficiency. Meropenem and its metabolite are effectively removed by hemodialysis. The dialysis clearance of the unchanged drug was 81 +/- 22 ml/min. Dosage adjustments of meropenem will be necessary in patients with severe renal impairment.

    Topics: Adult; Humans; Kidney Diseases; Meropenem; Middle Aged; Pyrroles; Renal Dialysis; Thienamycins; Uremia

1992
Pharmacokinetics of meropenem in subjects with renal insufficiency.
    European journal of clinical pharmacology, 1992, Volume: 42, Issue:5

    The pharmacokinetics of IV meropenem (500 mg over 30 min) has been studied in 6 healthy volunteers and 26 patients with various degrees of renal impairment. Blood samples were taken at different times over 24 h in healthy subjects and 36 to 48 h in uraemic patients, and four or five urine samples were collected over 24 or 48 h. Meropenem concentrations in plasma and urine were measured by a microbiological assay. The mean peak plasma concentration of meropenem ranged from 28 to 40 micrograms.ml-1 and was not affected by the degree of renal impairment. The terminal half-life of meropenem was approximately 1 h in subjects with normal kidney function and it was proportionately increased as renal function decreased. A significant linear relationship between total body clearance and creatinine clearance as well as between renal clearance and creatinine clearance was observed. The mean apparent volume of distribution at steady state was not significantly altered in uraemic patients. The mean cumulative urinary recovery of meropenem in healthy volunteers was 77% of the administered dose and it was significantly decreased in patients with renal impairment. Haemodialysis shortened the elimination half-life, from 9.7 h during the predialysis period to 1.4 h during the dialysis period. The dose of meropenem should be reduced in relation to the decrease in creatinine clearance.

    Topics: Adult; Glomerular Filtration Rate; Humans; Injections, Intravenous; Kidney Failure, Chronic; Meropenem; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Thienamycins; Time Factors; Uremia

1992